Results for tag: "Antihemophilic Factor"

The Antihemophilic Factor (AHF) market is a segment of the Hematological Drugs market. AHF is a recombinant protein used to treat hemophilia, a genetic disorder that impairs the body's ability to form blood clots. AHF is used to replace the missing clotting factor in hemophiliacs, allowing them to form clots and stop bleeding. AHF is administered intravenously or subcutaneously, and is available in both short-acting and long-acting forms. AHF is a highly specialized drug, and the market is dominated by a few large companies. These companies have invested heavily in research and development to create new and improved AHF products. They have also invested in marketing and distribution networks to ensure that their products are available to patients in need. Some of the major companies in the AHF market include Pfizer, Novo Nordisk, Bayer, Biogen, and Shire. Show Less Read more